Aetna Expands Coverage for Gallium-68 DOTATATE

August 16, 2018

After an initial push by SNMMI, Aetna has announced that it is expanding coverage of Gallium-68 DOTATATE. The company said, "This CPB is revised to state that gallium Ga 68 dotatate PET (NETSPOT) is considered medically necessary for diagnosis, staging and restaging of persons with primary and metastatic neuroendocrine tumors bearing somatostatin receptors when criteria are met." A copy of the new PET coverage policy can be found here.